Annexon (ANNX) Competitors

$5.37 -0.08 (-1.47%)

Closing price 04:00 PM Eastern

Extended Trading

$5.44 +0.07 (+1.23%)

As of 07:55 PM Eastern

ANNX vs. OGN, TNGX, ERAS, BEAM, and ORKA

Should you buy Annexon stock or one of its competitors? MarketBeat compares Annexon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Annexon include Organon & Co. (OGN), Tango Therapeutics (TNGX), Erasca (ERAS), Beam Therapeutics (BEAM), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry.

How does Annexon compare to Organon & Co.?

Annexon (NASDAQ:ANNX) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Annexon has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

77.4% of Organon & Co. shares are owned by institutional investors. 11.9% of Annexon shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organon & Co. has a net margin of 3.99% compared to Annexon's net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Organon & Co.	3.99%	99.95%	6.22%

Organon & Co. has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Organon & Co.	$6.22B	0.56	$187M	$0.93	14.37

Annexon presently has a consensus price target of $16.00, indicating a potential upside of 197.95%. Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 14.70%. Given Annexon's stronger consensus rating and higher possible upside, equities analysts plainly believe Annexon is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Organon & Co.	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57

In the previous week, Annexon had 17 more articles in the media than Organon & Co.. MarketBeat recorded 22 mentions for Annexon and 5 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.59 beat Annexon's score of 0.95 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Organon & Co. beats Annexon on 9 of the 14 factors compared between the two stocks.

How does Annexon compare to Tango Therapeutics?

Annexon (NASDAQ:ANNX) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Annexon has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

In the previous week, Annexon had 14 more articles in the media than Tango Therapeutics. MarketBeat recorded 22 mentions for Annexon and 8 mentions for Tango Therapeutics. Annexon's average media sentiment score of 0.95 beat Tango Therapeutics' score of 0.86 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon presently has a consensus price target of $16.00, indicating a potential upside of 197.95%. Tango Therapeutics has a consensus price target of $30.45, indicating a potential upside of 22.45%. Given Annexon's higher possible upside, equities analysts plainly believe Annexon is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

79.0% of Tango Therapeutics shares are owned by institutional investors. 11.9% of Annexon shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Annexon has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -50.17% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Tango Therapeutics	-151.15%	-50.17%	-37.99%

Tango Therapeutics has higher revenue and earnings than Annexon. Tango Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Tango Therapeutics	$62.38M	57.51	-$101.59M	-$0.87	N/A

Summary

Tango Therapeutics beats Annexon on 8 of the 13 factors compared between the two stocks.

How does Annexon compare to Erasca?

Erasca (NASDAQ:ERAS) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Erasca has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Annexon has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

In the previous week, Erasca had 3 more articles in the media than Annexon. MarketBeat recorded 25 mentions for Erasca and 22 mentions for Annexon. Annexon's average media sentiment score of 0.95 beat Erasca's score of 0.10 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annexon	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca presently has a consensus target price of $18.75, indicating a potential upside of 80.81%. Annexon has a consensus target price of $16.00, indicating a potential upside of 197.95%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

67.8% of Erasca shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 11.9% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Erasca's return on equity of -35.31% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Annexon	N/A	-101.19%	-75.99%

Erasca is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Summary

Erasca beats Annexon on 9 of the 12 factors compared between the two stocks.

How does Annexon compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

99.7% of Beam Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 11.9% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, Annexon has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Annexon. Beam Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.74	-$79.99M	-$0.68	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Annexon has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Annexon	N/A	-101.19%	-75.99%

In the previous week, Annexon had 10 more articles in the media than Beam Therapeutics. MarketBeat recorded 22 mentions for Annexon and 12 mentions for Beam Therapeutics. Annexon's average media sentiment score of 0.95 beat Beam Therapeutics' score of 0.72 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Annexon	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics currently has a consensus target price of $46.83, indicating a potential upside of 58.60%. Annexon has a consensus target price of $16.00, indicating a potential upside of 197.95%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Beam Therapeutics beats Annexon on 10 of the 15 factors compared between the two stocks.

How does Annexon compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 11.9% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Oruka Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market. Comparatively, Annexon has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Oruka Therapeutics' return on equity of -26.96% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.96%	-25.73%
Annexon	N/A	-101.19%	-75.99%

In the previous week, Annexon had 11 more articles in the media than Oruka Therapeutics. MarketBeat recorded 22 mentions for Annexon and 11 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.16 beat Annexon's score of 0.95 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics currently has a consensus target price of $120.80, indicating a potential upside of 89.05%. Annexon has a consensus target price of $16.00, indicating a potential upside of 197.95%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Oruka Therapeutics beats Annexon on 8 of the 12 factors compared between the two stocks.

Get Annexon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANNX vs. The Competition

Export

Metric	Annexon	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$892.94M	$3.40B	$6.29B	$12.40B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	N/A	18.98	20.89	25.59
Price / Sales	N/A	179.69	523.43	63.12
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	4.30	6.74	9.86	6.70
Net Income	-$206.69M	$24.11M	$3.55B	$333.77M
7 Day Performance	-2.72%	0.08%	-0.33%	0.45%
1 Month Performance	-7.41%	0.84%	1.34%	4.06%
1 Year Performance	205.11%	78.10%	41.10%	36.24%

Annexon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANNX Annexon	2.2446 of 5 stars	$5.37 -1.5%	$16.00 +198.0%	+211.4%	$892.94M	N/A	N/A	60	News Coverage Earnings Report Analyst Forecast Analyst Revision
OGN Organon & Co.	3.1511 of 5 stars	$13.35 -0.5%	$11.40 -14.6%	+58.1%	$3.50B	$6.22B	14.35	10,000	Positive News Ex-Dividend
TNGX Tango Therapeutics	2.7639 of 5 stars	$23.48 -0.6%	$22.44 -4.4%	+1,722.1%	$3.39B	$62.38M	N/A	90	Earnings Report Analyst Upgrade Gap Down High Trading Volume
ERAS Erasca	3.6832 of 5 stars	$10.40 -4.6%	$17.88 +71.9%	+686.5%	$3.23B	N/A	N/A	120	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Down
BEAM Beam Therapeutics	3.9838 of 5 stars	$31.47 -2.7%	$47.17 +49.9%	+76.5%	$3.23B	$139.74M	N/A	510	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANNX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annexon (ANNX) Competitors

ANNX vs. OGN, TNGX, ERAS, BEAM, and ORKA

How does Annexon compare to Organon & Co.?

Summary

How does Annexon compare to Tango Therapeutics?

Summary

How does Annexon compare to Erasca?

Summary

How does Annexon compare to Beam Therapeutics?

Summary

How does Annexon compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annexon (ANNX) Competitors

ANNX vs. OGN, TNGX, ERAS, BEAM, and ORKA

How does Annexon compare to Organon & Co.?

Which has more risk & volatility, ANNX or OGN?

Do insiders & institutionals believe in ANNX or OGN?

Is ANNX or OGN more profitable?

Which has preferable earnings & valuation, ANNX or OGN?

Do analysts recommend ANNX or OGN?

Does the media prefer ANNX or OGN?

Summary

How does Annexon compare to Tango Therapeutics?

Which has more risk & volatility, ANNX or TNGX?

Does the media prefer ANNX or TNGX?

Do analysts recommend ANNX or TNGX?

Do insiders & institutionals believe in ANNX or TNGX?

Is ANNX or TNGX more profitable?

Which has preferable earnings & valuation, ANNX or TNGX?

Summary

How does Annexon compare to Erasca?

Which has more volatility and risk, ERAS or ANNX?

Does the media prefer ERAS or ANNX?

Do analysts recommend ERAS or ANNX?

Do institutionals & insiders believe in ERAS or ANNX?

Is ERAS or ANNX more profitable?

Which has better earnings and valuation, ERAS or ANNX?

Summary

How does Annexon compare to Beam Therapeutics?

Do insiders and institutionals believe in BEAM or ANNX?

Which has more volatility & risk, BEAM or ANNX?

Which has preferable earnings & valuation, BEAM or ANNX?

Is BEAM or ANNX more profitable?

Does the media favor BEAM or ANNX?

Do analysts recommend BEAM or ANNX?

Summary

How does Annexon compare to Oruka Therapeutics?

Do insiders and institutionals believe in ORKA or ANNX?

Which has more volatility & risk, ORKA or ANNX?

Which has preferable earnings & valuation, ORKA or ANNX?

Is ORKA or ANNX more profitable?

Does the media favor ORKA or ANNX?

Do analysts recommend ORKA or ANNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools